SPECIAL REPORT
MOST SHARED
- How to Date a Wall Street Man
- Europe Shares End Lower, Hit by New Greek Concerns
- Unions Launch Strike in Greece
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- Bill Murray's View on the Economy
- The World's Best Beers
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Spent Keurig K-Cups Filling Up U.S. Landfills
- Greece Austerity Deal Runs Into Trouble Once Again
- Jobs You Can Do Forever
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- CEO to CEO: Our Roles Are Changing
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Tesla Unveils First SUV: Model X
- New York Fashion Week Hits the Runway as Colors Pop
- Greece Austerity Deal Runs Into Trouble Once Again
- Why Greece Will Default, Leave Eurozone
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- Diamond Investing: Why It's Not for the Faint of Heart
- Obama Backs Down on Birth Control Plan
- Israel Likely to Bomb Iran This Year: Political Analyst
- The World's Best Beers
- Users of Citibank Bill-Pay App Charged Twice
RSS FEED
Pharma's Market
Text Size 
There's No ME in aMYlin
 |
CNBC.com |
] is quoting me in a letter to shareholders. AMLN is engaged in an escalating proxy fight with billionaire activist investor Carl Icahn and another big investment firm, Eastbourne. The challengers want to install their own people on the Board of Directors and to presumably sell the company.
Amylin says maintaining the status quo and staying the course is the way to go. And the letter Kliff was telling me about is just the latest salvo.
As the May 27th shareholder meeting and the vote get closer the rhetoric is heating up.
For example, in the new letter Amylin says (all in caps and boldface type), "DO NOT BE MISLED BY ICAHN AND EASTBOURNE. THEIR ONLY PLAN IS TO SELL THE COMPANY AT THE WRONG TIME.". By the way, I think it's worth noting that AMLN put "at the wrong time" in there.
Anyway, while on the one hand I guess I'm flattered, on the other I'm a bit uncomfortable. I'm a reporter. I just cover the story. I don't want to become part of it. Ever.
I want to make absolutely clear to anyone who might try to misinterpret the use of my name in the SEC filing that the quote does not reflect my opinion of Amylin or Byetta or its prospects as a once-a-week injection for diabetes. It was lifted from my on-air CNBC coverage last week of the company's filing for FDA approval of once-a-week Byetta. Amylin is partners with Eli Lilly [LLY
Loading...
()
] and Alkermes [ALKS
Loading...
()
] on the product.
If you read the quote you'll notice that I source the projections for once-a-week Byetta's sales potential to analysts. It is not my analysis or my opinion. In journalism it's called attribution.
Interestingly, in a subsequent press release issued Monday morning about the new SEC filing containing the letter to shareholders there's now a supporting quote, in addition to mine, from an actual analyst.
I certainly don't object to being quoted. After all, that's what I do...quote people. I simply don't want Amylin's use of my quote to be misconstrued by anyone that it in any way means I'm taking sides here. I am not. I would never.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
